Global CRO Quintiles has expanded its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) lab. The lab, located in the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.
The Oss lab facility combines a cohort of employees with extensive industry experience, automated processes and a state-of-the-art facility equipped to increase high-quality throughput. In addition, the lab will bolster and enhance Quintiles' end-to-end clinical trial laboratory services.
"Adding this capability in Europe is a key step for our bioanalytical business and supports the strategy to increase our participation in the substantial European bioanalytical market," said Costa Panagos, senior vice president and global head of global central laboratories at Quintiles.
Currently, Quintiles' bioanalytical and ADME capabilities and work are managed out of three lab sites in the U.S. The new lab will be fully integrated with Quintiles' existing lab in Ithaca, N.Y., enabling the transfer of assays back and forth to accommodate global studies.
As part of Quintiles' bioanalytical and ADME lab services group, the new lab would become part of the recently announced clinical trials lab services joint venture with Quest Diagnostics. That transaction, which remains subject to regulatory approval and customary closing conditions, is anticipated to close in the third quarter. Until that transaction is completed, the new lab will continue to operate as part of Quintiles' bioanalytical and ADME lab network.
"The Oss laboratory will further enhance the scale, clinical trial expertise and diverse therapeutic experience that will be a cornerstone of the proposed joint venture with Quest Diagnostics," said Panagos, who will work as the new joint venture's CEO upon completion of the transaction. "The addition of the Oss laboratory is integral to the continued evolution of our laboratory business and we're excited about the benefits it can provide as part of a globally scaled and agile business for our customers today as well as in the future."